Bruce Schackman, PhD

Chief, Comparative Effectiveness and Outcomes

Comparative Effectiveness and Outcomes (Population Health Sciences)

Contact & profiles

brs2006@med.cornell.edu

Appointments

Professor of Population Health SciencesPrimary
Population Health Sciences · 2020–
Saul P. Steinberg Distinguished Professor of Healthcare Policy and Research
Population Health Sciences · 2016–
Professor of Healthcare Policy and Research in Psychiatry
Psychiatry · 2015–
Professor of Healthcare Policy and Research in Medicine
Medicine · 2014–
Professor
Weill Cornell Graduate School — Population Health Sciences

Past Appointments

Professor of Healthcare Policy and Research
Population Health Sciences · 2014–2020
Saul P. Steinberg Distinguished Professor of Psychiatry and Public Health
Population Health Sciences · 2015–2016
Professor of Public Health
Population Health Sciences · 2013–2013

Show all 7

Professor of Public Health in Medicine
Medicine · 2013–2013
Associate Professor of Public Health in Medicine
Medicine · 2013–2013
Associate Professor of Public Health
Population Health Sciences · 2007–2013
Assistant Professor of Public Health
Population Health Sciences · 2001–2007

Roles & Leadership

Associate Dean, Master's Programs
Weill Cornell Graduate School · 2025–

Centers

Education

Ph.D., Health Policy
Harvard University, 2001
M.B.A.
Harvard University, 1984
A.B., Social Studies
Harvard College, 1980

Overview

Dr. Schackman is the Director of CHERISH – The Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV - a multi-institutional Center of Excellence, funded by the National Institute on Drug Abuse (P30DA040500). CHERISH is a collaboration among researchers at Weill Cornell Medicine, Boston Medical Center, the University of Pennsylvania Leonard Davis Institute of Health Economics, and the University of Miami Miller School of Medicine. Dr. Schackman is the Saul P. Steinberg Distinguished Professor of Healthcare Policy & Research at Weill Cornell, where he conducts economic evaluations of the comparative effectiveness of health interventions alongside clinical trials and cohort studies, cost-effectiveness and comparative effectiveness simulation modeling studies, and implementation science studies—particularly relating to treatment of infectious diseases and substance use disorders. His current research includes economic evaluations of HIV and hepatitis C screening and treatment in substance use treatment settings, and economic evaluations of treatments for opioid use disorder.

Highlights

1
Harm reduction journal · 2023
AJAli Jalali SMSean M. Murphy BSBruce Schackman
PMID: 37853481PMCID: PMC10585909DOISenior author17 citations
2
Substance abuse · 2021
CNCzarina Navos Behrends BSBruce Schackman
PMID: 34666633PMCID: PMC9048167DOISenior author14 citations
3
JAMA network open · 2024
YBYuhua Bao BSBruce Schackman
PMID: 38980680PMCID: PMC11234232DOISenior author4 citations

Publications

239

Funding

46 View NIH portfolio on RePORTER ↗

Active

8 grants

Co-I
Columbia University-Weill Cornell Medicine CFAR (CU-WCM CFAR)
National Institute of Allergy and Infectious Diseases · 2026–2031 · via Columbia University
P30AI191337-01A1
PI
Health Economics of Substance Use Disorder, HCV, and HIV Treatment: Supporting Financial Sustainability, Advanced Methods, and Knowledge Translation
National Institute on Drug Abuse · 2015–2030· 6 renewals
P30DA040500-12
Co-I
Reversing Overdose Epidemics through Simulation, Collaboration, and Unified Efforts (RESCUE)
National Institute on Drug Abuse · 2024–2028 · via University of Minnesota
R33DA062346-01
PI
HEAL Data2Action Modeling and Economic Resource Center
National Institute on Drug Abuse · 2022–2027
U24DA057650-05
Sub-PI
Miami Dade County ASsessment of Phylogenics to Improve Resource Equity: MD ASPIRE
National Institute of Mental Health · 2022–2027 · via University of California, San Diego
R01MH132151-05
Sub-PI
Accelerating Implementation of Multilevel-strategies to Advance Long Acting Injectables for Underserved Populations (The ALAI UP Project)
Health Resources and Services Administration · 2024–2026 · via Columbia University
6 U1SHA46532-03-01
Co-I
CDC Overdose Data to Action: Local
Fund for Public Health in New York, Inc. · 2023–2026Contract
SA 241817-01
Co-I
Disparities in the Diffusion of Direct-Acting Antiviral Therapy for Hepatitis C among Baby Boomers: A Mixed-Methods Study
National Institute of Diabetes and Digestive and Kidney Diseases · 2020–2026
R01DK123205-01A1

Completed grants (38)

Co-I
Reducing Post-Hospital Mortality in HIV-Infected Adults in Tanzania
National Institute of Mental Health · 2018–2025
R01MH118107-01
Sub-PI
CHASE: An Innovative County-Level Public Health Response to the Opioid Epidemic in New York State
National Institute on Drug Abuse · 2019–2025 · via Columbia University
UM1DA049415-05
PI
DAT-18-06 Prevention and Rescue Of Fentanyl and Other Opioid Overdoses Using Optimized Naloxone Distribution Strategies (PROFOUND)
National Institute on Drug Abuse · 2019–2025
U01DA047408-05
Co-I
Health and Economic Outcomes of Treatment with Extended-Release Naltrexone Among Pre-Release Prisoners with Opioid Use Disorder
National Institute on Drug Abuse · 2019–2025
R01DA046721-01A1
PI
Simulation Modeling To Support The Public Health Response To The Opioid Crisis In North America
National Institute on Drug Abuse · 2021–2024
R13DA052198-04
PI
DAT 18-06 Feasibility and Acceptability of HIV, HCV, and Opioid Use Disorder Services in Syringe Service Programs
National Institute on Drug Abuse · 2009–2024· 5 renewals
R01DA027379-09S1
MPI
A Multi-Site Multi-Setting RCT of Integrated HIV Prevention and HCV Care for PWID
National Institute on Drug Abuse · 2017–2024 · via Columbia University
R01DA045713-05
MPI
Impact of Jail-Based Methadone on Overdose, Recidivism, HIV, and Health Outcomes and Costs in New York City, 2011-2017
National Institute on Drug Abuse · 2018–2024 · via New York University School of Medicine (Grossman)
R01DA045042-04
Sub-PI
Addiction Health Services Research Conference
National Institute on Drug Abuse · 2023–2024 · via University of Wisconsin
R13DA058506-01
Sub-PI
HEALing Communities Study: Data Coordinating Center
National Institute on Drug Abuse · 2019–2024 · via RTI International· 2 renewals
UM1DA049394-01
Sub-PI
A pragmatic trial of two strategies for implementing an effective eHealth HIV prevention program
National Institute of Mental Health · 2018–2023 · via Northwestern University
R01MH118213-03
MPI
Researching Effective Strategies to Prevent Opioid Death (RESPOND)
National Institute on Drug Abuse · 2018–2023 · via Boston Medical Center (Corporation)
R01DA046527-05
Co-I
Expanding FDA's Opioids Systems Model to Enable Economic Evaluations and Outcome Analyses of National Opioid Policies
United States Food & Drug Administration · 2020–2022 · via The General Hospital Corporation (dba Massachusetts General Hospital)
U01FD007064-01
Co-I
FANMI: Community Cohort Care for HIV-infected Adolescent Girls in Haiti
Eunice Kennedy Shriver National Institute of Child Health and Human Development · 2017–2022
R01HD091935-04
Sub-PI
A Cluster RCT to Increase HIV Testing in Substance Use Treatment Programs
National Institute on Drug Abuse · 2016–2022 · via Columbia University
R01DA043130-05
Co-I
PRimary care Opioid Use Disorders Treatment (PROUD) Trial
National Institute on Drug Abuse · 2019–2022 · via Kaiser Foundation Research Institute
UG1DA040314-04S4
Sub-PI
Evaluation of Community-based Drug User Health Hubs to Reduce Opioid Overdoses in NY State
Centers for Disease Control and Prevention · 2018–2022 · via Health Research INC (Center for Community Health)
R01CE003022-03-03
Sub-PI
Localized Economic Modeling to Optimize Public Health Strategies for HIV treatment and Prevention
National Institute on Drug Abuse · 2016–2021 · via Simon Fraser University
R01DA041747-05
PI
Economic Evaluation of Medication-Assisted Substance Abuse Treatment
National Institute on Drug Abuse · 2014–2020
R01DA035808-04
KP
Weill Cornell Medical College-New Jersey Medical School Clinical Trials Unit
National Institute of Allergy and Infectious Diseases · 2013–2020
UM1AI069419-12
Co-I
Conditional M. Tuberculosis Knockdown Mutants for TB Drug Development
Bill & Melinda Gates Foundation · 2017–2020
BMGF OPP1024065
PI
Enhanced Access to HIV Care for Drug Users in San Juan, Puerto Rico
National Institute on Drug Abuse · 2013–2020
R01DA035280-05
Sub-PI
HealthCall: Enhancing Brief Intervention for HIV Primary Care Alchohol Dependence
National Institute on Alcohol Abuse and Alcoholism · 2014–2019 · via Research Foundation for Mental Hygiene, Inc.
R01AA023163-05
MPI
The Florida Node Alliance of the National Drug Abuse Treatment Clinical Trials Network
National Institute on Drug Abuse · 2015–2019 · via University of Miami
UG1DA013720-19
PI
Consulting Agreement Amendment (Term Extension for Zack Rosen)
OneGreenOak, LLC · 2018–2019Contract
SA 184128-01
PI
Consulting Agreement Amendment No. 1 (Term extension)
John Mordecai · 2018–2019Contract
SA 184127-01
Sub-PI
Cost-Effectiveness of Preventing HIV Complications
National Institute of Allergy and Infectious Diseases · 2010–2018 · via The General Hospital Corporation (dba Massachusetts General Hospital)· 2 renewals
R37AI042006-20
Sub-PI
Project INSPIRE-NYC
Centers for Medicare & Medicaid Services · 2014–2018 · via Fund for Public Health in New York, Inc.
5 C1 CMS331330-04
PI
Supervised Injection Facility Feasibility Study
Fund for Public Health in New York, Inc. · 2017–2017Contract
FPHNY SA
Sub-PI
Intensive Models of HCV Care for Injection Drug Users
National Institute on Drug Abuse · 2012–2017 · via Yeshiva University
R01DA034086-06
Sub-PI
Simulation Modeling to Improve HIV/HCV Screening, Treatment and Care
National Institute on Drug Abuse · 2012–2016 · via The General Hospital Corporation (dba Massachusetts General Hospital)
R01DA031059-04
PI
Quality of Life Outcomes in Prescription and Injection Opioid Dependence
National Institute on Drug Abuse · 2012–2016
R01DA033424-03EWO
KP
Integrated vs. Separate Care for Hepatitis C, Substance Abuse, and HIV Prevention
National Institute on Drug Abuse · 2010–2015 · via State University of New York Downstate Medical Center
R01DA029512-03
MPI
HPTN 065 HIV Testing Cost Analysis
National Institutes of Health · 2013–2014 · via Family Health International
UM1AI068619-09
KP
Haiti AIDS Research Training: Models to Implementation
Fogarty International Center · 2009–2014 · via GHESKIO Centers
U2RTW006896-09
Sub-PI
Modeling the Impact of HIV Prevention Interventions
National Institute of Mental Health · 2010–2014 · via Harvard University
R01MH087328-04
Sub-PI
Pharmacogenomics of HIV Therapy
National Institute of Allergy and Infectious Diseases · 2009–2013 · via Vanderbilt University
R01AI077505-05
PI
HCV Treatment Cost-Effectiveness in 3 IDU Populations
NIDA · 2004–2010 · via NIH RePORTER
K01DA017179-05

Clinical research

Completed & closed trials (2)

PI
Feasibility and Acceptability of HIV, HCV, and Opioid Use Disorder Services in Syringe Service Programs
Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2024)
PI
HEALing Communities Study
Research Triangle Institute · CLOSED TO ACCRUAL (as of 2023)

News mentions

4 View all WCM news ↗

New Funding for Health Economics Research on Substance Use Disorder Treatments
October 30, 2025
A team led by Weill Cornell Medicine and University of Miami’s Miller School of Medicine investigators has been awarded a five-year, $4 million grant from the National Institute on Drug Abuse (NIDA) for health economics research.
Research Highlights Prevention Efforts in Fentanyl Overdoses
January 16, 2025
The overwhelming majority of those in New York City who obtained a naloxone kit to counteract opioid overdose had a high need for the drug, according to a new study by Weill Cornell Medicine investigators and the New York City Department of Health and Mental Hygiene.
Weill Cornell Medicine Awarded NIH Grant to Address Opioid Health Crisis
November 7, 2022
Weill Cornell Medicine has been awarded a five-year, $8.1 million grant from the National Institutes of Health (NIH) to support economic analysis, simulation modeling and other research approaches to help stem the national opioid epidemic.
Department of Population Health Sciences Established at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center
July 22, 2020
Weill Cornell Medicine and NewYork-Presbyterian have realigned the Department of Healthcare Policy and Research to address the intersection of research and practice. The newly named Department of Population Health Sciences, led by distinguished health services researcher, information scientist and leader Dr. Rainu Kaushal, aims to improve the health of populations through data-driven research, innovative technology and novel education programs.

Mentoring

1 All publications with mentees →

RY
Roger Ying
MD mentee · Class of 2019
- Spatial distribution and characteristics of HIV clusters in Ethiopia.
  Tropical medicine & international health : TM & IH · 2020
View all 1 →

External relationships

Other

Simon Fraser University